Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Trovagene's KRAS Test; Emory's Medical EmExome


Trovagene has launched a next-generation sequencing-based assay to test for KRAS oncogene mutations by assessing the urine of metastatic cancer patients with biopsy-proven KRAS mutations in their tumor.

The assay is designed to detect the seven most prevalent mutations in the KRAS oncogene and has a lower limit of detection of .04 percent, according to the company.

Emory Genetics Laboratory has launched the Medical EmExome, an exome sequencing test with enhanced coverage off 4,600 medically relevant genes. The test will cost $6,000 or $6,700 for a trio (see story, this issue).